Veru Dirección
Dirección controles de criterios 3/4
El CEO de Veru es Mitch Steiner , nombrado en Oct 2016, tiene una permanencia de 9.67 años. compensación anual total es $1.65M, compuesta por 50.7% salario y 49.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.42% de las acciones de la empresa, por valor de $1.67M. La antigüedad media del equipo directivo y de la junta directiva es de 8.2 años y 3.7 años, respectivamente.
Información clave
Mitch Steiner
Chief Executive Officer (CEO)
US$1.6m
Compensación total
| Porcentaje del salario del CEO | 50.69% |
| Permanencia del CEO | 9.7yrs |
| Participación del CEO | 4.4% |
| Permanencia media de la dirección | 8.2yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...
Aging Trends And FDA Clarity Will Unlock Opportunity
Veru’s future P/E has increased and its net profit margin has declined, indicating deteriorating profitability expectations, but analysts maintain their fair value estimate unchanged at $25.00. What's in the News Veru announced a novel modified release oral formulation for enobosarm in chronic weight loss, achieving target pharmacokinetics and leveraging proprietary delivery technology with positive Phase 2b efficacy and safety data.Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge
NasdaqCM:VERU 1 Year Share Price vs Fair Value Explore Veru's Fair Values from the Community and select yours Veru Inc...Veru Inc.'s (NASDAQ:VERU) 28% Share Price Surge Not Quite Adding Up
Veru Inc. ( NASDAQ:VERU ) shareholders have had their patience rewarded with a 28% share price jump in the last month...Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Summary Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts. Veru's strong Phase 2b data and market potential suggest a substantial upside despite notable risks, making it a classic speculative investment. While current valuation assigns a minimal probability of success, a positive launch could yield peak sales in the billions. Read the full article on Seeking Alpha
Enobosarm Phase III And Sabizabulin Tests Will Yield Mixed Prospects
Successful clinical trials indicate potential for regulatory approval and commercialization, enhancing future revenue and earnings.Veru Inc.'s (NASDAQ:VERU) 27% Price Boost Is Out Of Tune With Revenues
Those holding Veru Inc. ( NASDAQ:VERU ) shares would be relieved that the share price has rebounded 27% in the last...Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Veru (NASDAQ:VERU) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You
Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Veru Inc. ( NASDAQ:VERU ) share price has softened a substantial 35% over the previous 30 days, handing back much...The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Veru Inc. ( NASDAQ:VERU ) shareholders won't be pleased to see that the share price has had a very rough month...Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
The latest analyst coverage could presage a bad day for Veru Inc. ( NASDAQ:VERU ), with the analysts making...Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the Veru Inc. ( NASDAQ:VERU ) share price has dived 38% in the last thirty days...Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
How far off is Veru Inc. ( NASDAQ:VERU ) from its intrinsic value? Using the most recent financial data, we'll take a...Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$14m |
| Dec 31 2025 | n/a | n/a | -US$19m |
| Sep 30 2025 | US$2m | US$836k | -US$16m |
| Jun 30 2025 | n/a | n/a | -US$28m |
| Mar 31 2025 | n/a | n/a | -US$29m |
| Dec 31 2024 | n/a | n/a | -US$29m |
| Sep 30 2024 | US$2m | US$804k | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$35m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | n/a | n/a | -US$62m |
| Sep 30 2023 | US$5m | US$866k | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$126m |
| Mar 31 2023 | n/a | n/a | -US$136m |
| Dec 31 2022 | n/a | n/a | -US$116m |
| Sep 30 2022 | US$6m | US$761k | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | n/a | n/a | -US$16m |
| Sep 30 2021 | US$2m | US$618k | US$7m |
| Jun 30 2021 | n/a | n/a | -US$144k |
| Mar 31 2021 | n/a | n/a | -US$476k |
| Dec 31 2020 | n/a | n/a | US$2m |
| Sep 30 2020 | US$1m | US$502k | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$13m |
| Sep 30 2019 | US$800k | US$392k | -US$12m |
Compensación vs. Mercado: La compensación total de Mitch($USD1.65M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD635.09K).
Compensación vs. Ingresos: La compensación de Mitch ha sido consistente con los resultados de la empresa en el último año.
CEO
Mitch Steiner (65 yo)
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$1.65m | 4.42% $ 1.7m | |
| Vice Chairman & Chief Corporate Officer | 9.7yrs | US$769.42k | 4.99% $ 1.9m | |
| Chief Scientific Officer | 7.8yrs | US$941.01k | 0.0031% $ 1.2k | |
| CFO & Chief Administrative Officer | 8.5yrs | US$1.55m | 0.060% $ 22.6k | |
| Executive Director of Investor Relations & Corporate Communications | 7.2yrs | sin datos | sin datos | |
| Executive VP | less than a year | sin datos | sin datos | |
| Executive Vice President of Corporate Development | 9.4yrs | sin datos | sin datos | |
| Executive Vice President of FC2 Global Operations | no data | US$193.01k | sin datos | |
| Executive Vice President of Global Clinical Operations | 8.2yrs | sin datos | sin datos | |
| Executive Vice President of Quality & Regulatory Affairs | 7.3yrs | sin datos | sin datos | |
| Executive Vice President of Operations - GPS Sales | no data | sin datos | sin datos | |
| Senior Vice President of Finance | no data | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de VERU es experimentado (8.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$1.65m | 4.42% $ 1.7m | |
| Vice Chairman & Chief Corporate Officer | 9.7yrs | US$769.42k | 4.99% $ 1.9m | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
| Board Observer | 9.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
| Independent Director | 8.3yrs | US$61.22k | 0.16% $ 58.7k | |
| Independent Director | 5.1yrs | US$58.04k | 0.0061% $ 2.3k | |
| Member of Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
| Independent Director | 1.8yrs | US$42.76k | 0.14% $ 52.6k | |
| Independent Director | 5.8yrs | US$51.46k | 0.0092% $ 3.5k | |
| Member of Scientific Advisory Board | 2.3yrs | sin datos | sin datos |
Junta con experiencia: La junta directiva de VERU se considera experimentada (3.7 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/03 05:18 |
| Precio de las acciones al final del día | 2026/06/03 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Veru Inc. está cubierta por 4 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Edward Nash | Canaccord Genuity |
| Yuchen Ding | Jefferies LLC |
| Leland Gershell | Oppenheimer & Co. Inc. |